静脉内 (IV) 和/或瘤内 (IT) 博莱霉素的电化学疗法 (ECT) 在治疗不可切除的猫皮肤鳞状细胞癌 (cSCC) 方面显示出相当大的疗效，反应率高达 95%，但其他化疗方案尚未调查。这项前瞻性多中心研究的目的是比较使用 IT 和静脉注射卡铂 (IV   IT)、静脉注射卡铂 (IV) 或静脉注射博莱霉素进行 ECT 治疗的 cSCC 猫的总体缓解率 (ORR) 和无进展间隔 (PFI) （四）。三个中心总共 44 只患有不可切除的 cSCC 的猫被招募，并使用卡铂 IV  IT (n = 10)、卡铂 IV (n = 11) 或博来霉素 IV (n = 23) 进行 ECT 治疗。根据 RECIST 标准，在治疗后 2 周和 4 周记录治疗反应，并对患者进行随访，直至疾病进展和/或死亡。所有三组在年龄、性别、体重和病变大小方面都具有可比性。不良事件通常是轻微的、局部的并且组间相似。 ORR 分别为 90.0%（卡铂 IV  IT）、90.9%（卡铂 IV）和 95.6%（博来霉素 IV），无显着差异 (p = 0.79)。卡铂 IV  IT 或卡铂 IV 未达到中位 PFI，博来霉素 IV 为 566 天，三组之间无显着差异 (p = 0.81)。这项研究表明，使用 IV 或 IV  IT 卡铂进行 ECT 是治疗 cSCC 的合理替代治疗选择，并且需要进一步研究来比较治疗方案之间的结果。© 2024 作者。约翰·威利出版的《兽医和比较肿瘤学》

Electrochemotherapy (ECT) with intravenous (IV) and/or intratumoral (IT) bleomycin has shown considerable efficacy in the treatment of non-resectable feline cutaneous squamous cell carcinoma (cSCC), boasting response rates of up to 95%, but other chemotherapy protocols have not yet been investigated. The objective of this prospective multicentre study was to compare the overall response rate (ORR) and progression-free interval (PFI) between cats with cSCC treated with ECT using IT and IV carboplatin (IV + IT), IV carboplatin (IV) or IV bleomycin (IV). A total of 44 cats with unresectable cSCC across three centres were enrolled and treated with ECT using carboplatin IV + IT (n = 10), carboplatin IV (n = 11) or bleomycin IV (n = 23). Treatment response according to RECIST criteria was recorded at 2 and 4 weeks post-treatment, and patients were followed until disease progression and/or death. All three groups were comparable regarding age, sex, weight, and lesion size. Adverse events were generally mild, localised and similar between groups. ORRs were 90.0% (carboplatin IV + IT), 90.9% (carboplatin IV) and 95.6% (bleomycin IV) and were not significantly different (p = 0.79). Median PFI was not reached for carboplatin IV + IT or carboplatin IV and was 566 days for bleomycin IV, with no significant difference between the three groups (p = 0.81). This study suggests that ECT using IV or IV + IT carboplatin is a reasonable alternative therapeutic option for managing cSCC, and further studies are warranted to compare outcomes between treatment protocols.© 2024 The Author(s). Veterinary and Comparative Oncology published by John Wiley & Sons Ltd.